Liu Mo, Zhang Zi-Xu, Wang Jia-Hua, Guo Rui-Bo, Zhang Lu, Kong Liang, Yu Yang, Zang Juan, Liu Yang, Li Xue-Tao
School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China; Shenyang Key Laboratory of Chinese Medicine targeted Delivery Key laboratory, China.
School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China; Shenyang Key Laboratory of Chinese Medicine targeted Delivery Key laboratory, China; Key Laboratory of Ministry of Education for TCM Viscera-State Theory and Applications, Liaoning University of Traditional Chinese Medicine, China.
Int J Biol Macromol. 2025 Feb;290:138960. doi: 10.1016/j.ijbiomac.2024.138960. Epub 2024 Dec 19.
Ovarian cancer, a highly lethal form of gynecological cancer globally, has witnessed notable advancements in its treatment through the integration of nanotechnology and immunotherapy. Here, we designed a novel astragalus polysaccharide vector (PDA), encapsulating podophyllotoxin (PPT), and modifying methotrexate (DSPE-PEG-MTX) on its surface for targeting ovarian cancer cells with high folate receptor expression. We prepared novel MTX-modified PPT-loaded astragalus polysaccharide micelles (MTX-PPT-micelles) by dialysis method and evaluated their characterization, stability, safety and targeting ability. EDU proliferation, apoptosis, wound healing, and macrophage polarization experiments were performed, and a mouse ectopic tumor model and a lung metastasis model were established to evaluate the antitumor effects of MTX-PPT-micelles. The prepared MTX-PPT-micelles had appropriate particle size, good stability and safety, and were able to achieve slow drug release. In vitro and in vivo experiments showed that MTX-PPT-micelles significantly enhanced tumor uptake and apoptosis, and significantly inhibited tumor proliferation, invasion and metastasis processes. In addition, MTX-PPT-micelles could improve tumor immunosuppression by shifting tumor-associated macrophages from M2 to M1 phenotype. In conclusion, this study successfully constructed a novel nano-delivery system to achieve targeted therapy for ovarian cancer by combating tumor cells with immunomodulatory effects on tumor-associated macrophages.
卵巢癌是全球范围内一种极具致死性的妇科癌症,通过纳米技术与免疫疗法的结合,其治疗已取得显著进展。在此,我们设计了一种新型黄芪多糖载体(PDA),包封鬼臼毒素(PPT),并在其表面修饰甲氨蝶呤(DSPE-PEG-MTX),以靶向高表达叶酸受体的卵巢癌细胞。我们通过透析法制备了新型甲氨蝶呤修饰的负载鬼臼毒素的黄芪多糖胶束(MTX-PPT-胶束),并评估了其表征、稳定性、安全性和靶向能力。进行了EDU增殖、凋亡愈合和巨噬细胞极化实验,并建立了小鼠异位肿瘤模型和肺转移模型,以评估MTX-PPT-胶束的抗肿瘤作用。所制备的MTX-PPT-胶束具有合适的粒径、良好的稳定性和安全性,且能够实现药物缓慢释放。体外和体内实验表明,MTX-PPT-胶束显著增强肿瘤摄取和凋亡,并显著抑制肿瘤增殖、侵袭和转移过程。此外,MTX-PPT-胶束可通过将肿瘤相关巨噬细胞从M2表型转变为M1表型来改善肿瘤免疫抑制。总之,本研究成功构建了一种新型纳米递送系统,通过对抗肿瘤细胞并对肿瘤相关巨噬细胞产生免疫调节作用,实现对卵巢癌的靶向治疗。